ATE532073T1 - Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels - Google Patents
Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegelsInfo
- Publication number
- ATE532073T1 ATE532073T1 AT04765681T AT04765681T ATE532073T1 AT E532073 T1 ATE532073 T1 AT E532073T1 AT 04765681 T AT04765681 T AT 04765681T AT 04765681 T AT04765681 T AT 04765681T AT E532073 T1 ATE532073 T1 AT E532073T1
- Authority
- AT
- Austria
- Prior art keywords
- risk
- subject
- determining
- galectin
- thrombospondin
- Prior art date
Links
- 102000000802 Galectin 3 Human genes 0.000 title abstract 2
- 108010001517 Galectin 3 Proteins 0.000 title abstract 2
- 102100029529 Thrombospondin-2 Human genes 0.000 title abstract 2
- 108010060887 thrombospondin 2 Proteins 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title 1
- 239000003550 marker Substances 0.000 abstract 3
- 230000009787 cardiac fibrosis Effects 0.000 abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078161A EP1522857A1 (en) | 2003-10-09 | 2003-10-09 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| PCT/EP2004/010879 WO2005040817A1 (en) | 2003-10-09 | 2004-09-27 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE532073T1 true ATE532073T1 (de) | 2011-11-15 |
Family
ID=34306912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04765681T ATE532073T1 (de) | 2003-10-09 | 2004-09-27 | Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7888137B2 (enExample) |
| EP (4) | EP1522857A1 (enExample) |
| JP (5) | JP4840744B2 (enExample) |
| CN (2) | CN1879022B (enExample) |
| AT (1) | ATE532073T1 (enExample) |
| AU (2) | AU2004284496C1 (enExample) |
| CA (2) | CA2842308A1 (enExample) |
| CY (2) | CY1112359T1 (enExample) |
| DK (2) | DK2317324T3 (enExample) |
| ES (2) | ES2530567T3 (enExample) |
| PL (2) | PL2317324T3 (enExample) |
| PT (2) | PT2317324E (enExample) |
| SI (2) | SI1682907T1 (enExample) |
| WO (1) | WO2005040817A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| WO2008037720A2 (en) * | 2006-09-25 | 2008-04-03 | Universiteit Maastricht | Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
| WO2008091948A2 (en) * | 2007-01-23 | 2008-07-31 | University Of Virginia Patent Foundation | Galectin-3-binding, protein as a biomarker of cardiovascular disease |
| ATE534912T1 (de) * | 2007-09-17 | 2011-12-15 | Bg Medicine Inc | Beurteilung des risikos von kongestiver herzinsuffizienz bei patienten, die mit einem peroxisom-proliferator-aktivator-rezeptor-gamma agonisten oder einem thiazolidindion behandelt werden oder möglicherweise damit behandelt werden sollen |
| EP3971570A3 (en) * | 2008-10-29 | 2022-11-09 | BG Medicine, Inc. | Galectin-3 immunoassay |
| JP5702386B2 (ja) * | 2009-08-25 | 2015-04-15 | ビージー メディシン， インコーポレイテッド | ガレクチン−３および心臓再同期療法 |
| EP2588111A1 (en) * | 2010-07-02 | 2013-05-08 | BG Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| US8703433B2 (en) * | 2010-10-18 | 2014-04-22 | Hideaki Hara | Marker for amyotrophic lateral sclerosis, and use thereof |
| EP2460890A1 (en) | 2010-12-01 | 2012-06-06 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases |
| MX2013008839A (es) * | 2011-01-31 | 2013-11-04 | Bg Medicine Inc | Uso de galectina-3 para detectar y diagnosticar insuficiencia cardiaca posterior al sindrome coronario agudo. |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| AR086543A1 (es) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
| ES2669068T3 (es) * | 2011-12-08 | 2018-05-23 | Eliaz Therapeutics, Inc | Reducción de niveles de galectina-3 mediante plasmaféresis |
| US20150253314A1 (en) * | 2012-09-27 | 2015-09-10 | Siemens Healthcare Diagnostics Inc. | Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension |
| JP6366598B2 (ja) * | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
| AU2016207734A1 (en) | 2015-01-18 | 2017-08-03 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker |
| DE112016002393B4 (de) * | 2015-05-28 | 2023-11-02 | Kyocera Corporation | Schneidwerkzeug |
| CN112553335A (zh) * | 2020-12-17 | 2021-03-26 | 核工业总医院 | 肾细胞癌生物标志物及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632901A (en) | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US6319676B1 (en) | 1995-05-02 | 2001-11-20 | Carter Wallace, Inc. | Diagnostic detection device and method |
| BE1010935A7 (nl) * | 1997-02-19 | 1999-03-02 | Delanghe Joris Richard Siegfri | Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen. |
| AU7590198A (en) | 1997-06-10 | 1998-12-30 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| US20060166276A1 (en) * | 1997-09-05 | 2006-07-27 | Lung Health Diagnostics Pty Ltd | Method of diagnosis and agents useful for same |
| NZ503175A (en) * | 1997-09-05 | 2002-11-26 | Univ Southern Australia | A method of diagnosing lung damage by measuring SP-A, SP-B, SP-C and SP-D levels |
| KR100529198B1 (ko) * | 1997-10-24 | 2005-11-17 | 시오노기세이야쿠가부시키가이샤 | 나트륨 이뇨 펩티드의 분해 억제방법 및 이 방법을 이용한개량된 나트륨 이뇨 펩티드 측정방법 |
| DK1702623T3 (da) * | 1998-04-02 | 2009-01-19 | Genentech Inc | Anvendelse af interferon-gamma til behandling af hjertehypertrofi |
| EP1151304B9 (de) * | 1999-01-29 | 2008-06-04 | Roche Diagnostics GmbH | VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP |
| WO2001002866A1 (en) * | 1999-02-19 | 2001-01-11 | University Of Iowa Research Foundation | Diagnostics and therapeutics for arterial wall disruptive disorders |
| JP2003507076A (ja) * | 1999-08-20 | 2003-02-25 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５ |
| WO2001057252A2 (en) | 2000-02-04 | 2001-08-09 | Aeomica, Inc. | Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes |
| WO2001077389A2 (en) | 2000-04-05 | 2001-10-18 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| KR100395254B1 (ko) * | 2000-10-30 | 2003-08-21 | (주)자리타 바이오텍 | 종양 발생 예측 키트 |
| AU2002220266A1 (en) * | 2000-11-09 | 2002-05-21 | Millennium Pharmaceuticals, Inc. | Methods for the identification and the treatment of cardiovascular disease |
| WO2002038794A2 (en) * | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| WO2002046475A2 (en) * | 2000-12-08 | 2002-06-13 | Curagen Corporation | Method of detecting and treating tuberous sclerosis complex associated disorders |
| JP4035562B2 (ja) * | 2001-01-31 | 2008-01-23 | 国立大学法人富山大学 | ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット |
| US7041449B2 (en) * | 2001-03-19 | 2006-05-09 | Wisconsin Alumni Research Foundation | Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice |
| US20060019235A1 (en) * | 2001-07-02 | 2006-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular and functional profiling using a cellular microarray |
| US7447594B2 (en) * | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US20030099958A1 (en) * | 2001-09-05 | 2003-05-29 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
| GB0124145D0 (en) | 2001-10-08 | 2001-11-28 | Bayer Ag | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease |
| US20060141493A1 (en) * | 2001-11-09 | 2006-06-29 | Duke University Office Of Science And Technology | Atherosclerotic phenotype determinative genes and methods for using the same |
| CA2483105C (en) * | 2002-05-13 | 2011-05-10 | Arexis Ab | Autoimmune conditions and nadph oxidase defects |
| AU2003290537A1 (en) | 2002-10-24 | 2004-05-13 | Duke University | Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications |
| JP2006514554A (ja) * | 2002-11-21 | 2006-05-11 | ワイス | 腎細胞癌および他の固形腫瘍の診断法 |
| EP1431399A1 (en) * | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| US6889083B2 (en) | 2003-04-21 | 2005-05-03 | Medtronic, Inc. | Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes |
| US20070105105A1 (en) * | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| US20060257946A1 (en) * | 2003-06-06 | 2006-11-16 | Ciphergen Biosystems, Inc | Serum biomarkers in ischaemic heart disease |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| EP1560025A3 (en) * | 2003-10-03 | 2011-09-07 | F. Hoffmann-La Roche AG | Specific markers for diabetes |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| DE10347436B4 (de) | 2003-10-13 | 2007-08-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP) |
| EP1720562A4 (en) | 2004-01-15 | 2009-10-28 | Scios Inc | METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE |
| WO2006026074A2 (en) | 2004-08-04 | 2006-03-09 | Duke University | Atherosclerotic phenotype determinative genes and methods for using the same |
| CA2596469A1 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services | Biomarkers for tissue status |
| WO2006102497A2 (en) * | 2005-03-22 | 2006-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease |
| US7632634B2 (en) * | 2005-04-15 | 2009-12-15 | University Of Maryland Biotechnology Institute | Method and assay for early diagnosis of prostate cancer |
| US9592970B2 (en) | 2008-07-17 | 2017-03-14 | Toby D. Henderson | Robotic gantry with end effector for product lifting |
| EP3971570A3 (en) | 2008-10-29 | 2022-11-09 | BG Medicine, Inc. | Galectin-3 immunoassay |
| JP5702386B2 (ja) | 2009-08-25 | 2015-04-15 | ビージー メディシン， インコーポレイテッド | ガレクチン−３および心臓再同期療法 |
-
2003
- 2003-10-09 EP EP03078161A patent/EP1522857A1/en not_active Withdrawn
-
2004
- 2004-09-27 PT PT101863314T patent/PT2317324E/pt unknown
- 2004-09-27 ES ES10186331T patent/ES2530567T3/es not_active Expired - Lifetime
- 2004-09-27 EP EP04765681A patent/EP1682907B1/en not_active Expired - Lifetime
- 2004-09-27 JP JP2006530040A patent/JP4840744B2/ja not_active Expired - Fee Related
- 2004-09-27 ES ES04765681T patent/ES2377012T3/es not_active Expired - Lifetime
- 2004-09-27 PT PT04765681T patent/PT1682907E/pt unknown
- 2004-09-27 PL PL10186331T patent/PL2317324T3/pl unknown
- 2004-09-27 DK DK10186331.4T patent/DK2317324T3/en active
- 2004-09-27 US US10/575,745 patent/US7888137B2/en active Active
- 2004-09-27 EP EP14192739.2A patent/EP2919012A1/en not_active Withdrawn
- 2004-09-27 DK DK04765681.4T patent/DK1682907T3/da active
- 2004-09-27 CN CN2004800332637A patent/CN1879022B/zh not_active Expired - Fee Related
- 2004-09-27 SI SI200431813T patent/SI1682907T1/sl unknown
- 2004-09-27 AU AU2004284496A patent/AU2004284496C1/en not_active Ceased
- 2004-09-27 CA CA2842308A patent/CA2842308A1/en not_active Abandoned
- 2004-09-27 SI SI200432221T patent/SI2317324T1/sl unknown
- 2004-09-27 CA CA2542033A patent/CA2542033C/en not_active Expired - Lifetime
- 2004-09-27 CN CN201210321227.7A patent/CN102998458B/zh not_active Expired - Fee Related
- 2004-09-27 WO PCT/EP2004/010879 patent/WO2005040817A1/en not_active Ceased
- 2004-09-27 AT AT04765681T patent/ATE532073T1/de active
- 2004-09-27 PL PL04765681T patent/PL1682907T3/pl unknown
- 2004-09-27 EP EP10186331.4A patent/EP2317324B1/en not_active Expired - Lifetime
-
2009
- 2009-10-19 AU AU2009227844A patent/AU2009227844B2/en not_active Ceased
-
2010
- 2010-07-26 JP JP2010167334A patent/JP2010279378A/ja not_active Withdrawn
- 2010-10-28 US US12/914,329 patent/US8084276B2/en not_active Expired - Fee Related
-
2011
- 2011-04-12 JP JP2011088342A patent/JP5580774B2/ja not_active Expired - Lifetime
- 2011-11-23 US US13/304,145 patent/US20120220532A1/en not_active Abandoned
-
2012
- 2012-02-01 CY CY20121100108T patent/CY1112359T1/el unknown
-
2013
- 2013-03-08 US US13/791,350 patent/US20130189716A1/en not_active Abandoned
-
2014
- 2014-02-06 JP JP2014021394A patent/JP5789009B2/ja not_active Expired - Lifetime
- 2014-05-05 US US14/269,707 patent/US20150037353A1/en not_active Abandoned
-
2015
- 2015-02-12 CY CY20151100136T patent/CY1116147T1/el unknown
- 2015-04-13 JP JP2015081540A patent/JP2015171365A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE532073T1 (de) | Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels | |
| DE60327354D1 (de) | Diagnostischer assay zur bestimmung einer zellvermittelten immunantwort | |
| DE60041355D1 (de) | Verfahren zur detektion von erkrankungen | |
| ATE319093T1 (de) | Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen | |
| ATE459578T1 (de) | Entsalzungsschiff sowie verfahren zur herstellung von entsalztem wasser | |
| ATE331217T1 (de) | Modulares fluorimeter und verfahren zu seiner verwendung zur erkennung eines oder mehrerer fluorophore | |
| ATE458201T1 (de) | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 | |
| EP0713093A3 (en) | Improved method for colorimetric determination of the concentration of white blood cells in a body fluid | |
| DE60033380D1 (de) | Verfahren zur quantifizierung der zahl von leukozyten in einer blutprobe | |
| DE60217351D1 (de) | Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens | |
| DE602005019475D1 (de) | Verfahren zur Bestimmung einer anfänglichen Nukleinsäurekonzentration anhand von real-time Amplifikationsdaten | |
| DE60335276D1 (de) | Verfahren zur umrechnung von venösen blutwerten in arterielle blutwerte, system zur verwendung der methode | |
| DE112006002354A5 (de) | Analyseverfahren zur Bestimmung eines Organfunktionsparameters unter bevorzugter Verwendung einer wässrigen C-Methacetin-Lösung | |
| DE59009364D1 (de) | Verfahren zur quantitativen Bestimmung zumindest eines chemischen Parameters eines Probenmediums. | |
| ATE482398T1 (de) | Verfahren zur stratifizierung von herzinsuffizienz | |
| DE60020347D1 (de) | Verfahren zur herstellung einer matrize von chemischen oder biologischen molekülsequenzen für eine chemische oder biologische analysevorrichtung | |
| EP1669761A3 (de) | Verfahren zur automatischen Bestimmung des endogenen Thrombinpotenzials | |
| ATE323282T1 (de) | VERFAHREN ZUR BESTIMMUNG EINES ERHÖHTEN RISIKOS EINER FRAU, EIN FOETUS MIT DEM ßDOWN-SYNDROMß ZU TRAGEN | |
| ATE423310T1 (de) | Verfahren und mittel zur bestimmung von gesamtsäure | |
| ATE357538T1 (de) | Verfahren zur kit genotypierung von schweinen | |
| EP1605260A3 (de) | Verfahren und Testkit zur Bestimmung des organisch gebundenen Kohlenstoffs (TOC) | |
| ATE465411T1 (de) | Verfahren zur bestimmung von anfälligkeit einer person zur infektion | |
| ATE470154T1 (de) | Verfahren zur bewertung von insulinresistenz | |
| DE602006013201D1 (de) | Verfahren zur bewertung der nierenfunktion einer k | |
| RU2003134132A (ru) | Способ экспресс-определения кальция в моче |